Takeda’s TAKHZYRO (lanadelumab) is now approved in Europe as a subcutaneous injection treatment for hereditary angioedema in patients 12 years old and above and in adults.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Japan’s MHLW Approves Takeda’s HYQVIA Subcutaneous Injection to Treat Agammaglobulinemia or Hypogammaglobulinemia

By Feliza Mirasol

January 3rd 2025

The approval makes HYQVIA [Immune Globulin Infusion 10% (human) with Recombinant Human Hyaluronidase] the first and only facilitated subcutaneous immunoglobulin to be approved in Japan to treat these disorders.

Medicine background with packs of pills, glass bottle, nasal spray and ampoules on the beige background with copy space | Image Credit: © Evgeniya Sheydt - © Evgeniya Sheydt/Stock.Adobe.com

Exploring Innovative Means for Biologics Delivery

By Feliza Mirasol

September 10th 2024

Alternative delivery methods for biologics continues to be explored that offer less invasive, less painful administration.

Takeda’s Subcutaneous Immunoglobulin Receives FDA Approval for Maintenance Therapy of Rare Neuromuscular Disorder

By Feliza Mirasol

January 24th 2024

Takeda has received FDA approval for HYQVIA, a subcutaneous immunoglobulin for the maintenance treatment of chronic inflammatory demyelinating polyneuropathy.